The $8.2M Series A investment round was led by Alpha Edison, Acre Venture Partners, and other strategic investors including former NBA all-star and investor Baron Davis, and founder of SimplyProtein Cathy Richards. The new investors join The Production Board, a venture foundry which led the seed round.
“This funding represents a significant milestone for Muniq and our team at UR Labs. This raise confirms the significance of the unmet need and opportunity that we’re addressing. There are so many people in need of better solutions to regain control of their health, and we have the opportunity to really help people with products that are not only natural & effective but also really enjoyable and accessible. This is just a step in our journey, though, as we’re definitely just getting started and have SO many more lives to impact,” said Marc Washington, the founder and CEO of Uplifting Results Labs, the company behind Muniq.
Food as medicine
Muniq’s patent-pending line of nutritional shakes feed the gut with resistant starch, a prebiotic fiber that promotes a healthy gut microbiome, improves the body’s natural ability to manage blood sugar and support immune health.
Muniq uses 'food as medicine' to harness the power of the gut microbiome to effectively address prevalent chronic health conditions that disproportionately impact people of color.
“I created Muniq in honor of my late sister, Monica, who suffered from diabetes and other chronic health issues,” explained Washington. “It’s always been my aspiration to help people regain control over underlying conditions, with products that can literally transform their health and that actually taste good. I am inspired every time I hear about the life-changing impact Muniq is having on our customers’ lives. And personally, as a Black founder, I am passionate about Muniq being part of the solution to help address the vast health disparities affecting Black and Brown communities.”
Muniq’s nutritional shakes are formulated with scientifically-proven ingredients including prebiotic resistant starch, that can dramatically improve blood sugar control, weight management, digestive health, and more.
“Muniq has established a solid foundation in science and efficacy based on the rapidly emerging clinical research on the gut microbiome. The life-changing results experienced by Muniq customers exemplify the brand’s vast potential to address some of the most pressing health epidemics of our time,” said Nate Redmond, managing partner at Alpha Edison.
“We have always been committed to a foundation based on science and efficacy, and this funding enables us to advance primary clinical research around our solutions and their impact on health,” said Washington.
In addition to clinical research, Washington told us that the funding will also help raise brand awareness, add members to the internal team and expand their product offerings.
Washington was a recent guest on the NutraCast podcast. You can listen to it here.